Last reviewed · How we verify

NCT06653218

Efficacy and Safety of Stellate Ganglion Block With Lidocaine Combined Platelet-rich Plasma to Treat Chronic Migraine

Completed Last updated 12 February 2026
What this trial tests

trial testing No interventions in Platelet-rich Plasma in 200 participants. Completed in 30 September 2025.

Timeline
20 October 2024
Primary endpoint
30 June 2025
30 September 2025

Quick facts

Lead sponsorBeijing Tiantan Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment200
Start date20 October 2024
Primary completion30 June 2025
Estimated completion30 September 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Adults 18 to 75, any sex, with Platelet-rich Plasma or Chronic Migraine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, prospective, observational, propensity score matching, cohort, and assessor-blinded study designed to compare the effectiveness and safety of lidocaine combined Platelet-rich plasma (PRP) acting on SGB versus lidocaine alone acting on SGB in patients with CM.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No interventions

Trials testing the same drug.

Other recruiting trials for Platelet-rich Plasma

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06653218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing